A phase I open label dose escalation and dose-expansion study to evaluate the safety toloerability pharmcokinetics immunogenicity and antitumor activate of Medi-9447 alone and in combination with MEDI
Clinical Trial Grant
Awarded By
MedImmune, Inc.
Start Date
October 1, 2015
End Date
September 30, 2022
Awarded By
MedImmune, Inc.
Start Date
October 1, 2015
End Date
September 30, 2022